Recognizing that Aβ inhibits NO signaling by suppressing sGC activity through CD36 and CD47 may clarify Aβ's role in Alzheimer's disease pathogenesis and could lead to novel therapeutics aimed at limiting the adverse effects of Aβ in the brain. This evidence concerns the gene CD47 and Alzheimer disease.